USANA Health Sciences, Inc. (NYSE:USNA – Get Rating) insider Brent Neidig sold 1,400 shares of the stock in a transaction on Thursday, June 16th. The stock was sold at an average price of $70.93, for a total value of $99,302.00. Following the completion of the sale, the insider now directly owns 1,406 shares in the company, valued at $99,727.58. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Shares of USNA traded down $0.26 during trading hours on Friday, reaching $69.97. 427 shares of the company’s stock traded hands, compared to its average volume of 58,975. The firm has a market capitalization of $1.34 billion, a price-to-earnings ratio of 12.98 and a beta of 0.84. USANA Health Sciences, Inc. has a twelve month low of $67.01 and a twelve month high of $103.95. The business’s fifty day simple moving average is $74.41 and its two-hundred day simple moving average is $86.07.
USANA Health Sciences (NYSE:USNA – Get Rating) last issued its quarterly earnings results on Tuesday, April 26th. The company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. The company had revenue of $272.87 million for the quarter, compared to analyst estimates of $270.80 million. USANA Health Sciences had a return on equity of 27.04% and a net margin of 9.41%. During the same period last year, the company earned $1.45 earnings per share. On average, research analysts forecast that USANA Health Sciences, Inc. will post 5.28 earnings per share for the current fiscal year.
Whether you’re looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today’s futures markets!
USNA has been the topic of several analyst reports. DA Davidson dropped their target price on USANA Health Sciences from $86.00 to $76.00 in a research report on Wednesday, April 27th. StockNews.com lowered USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 26th.
Large investors have recently added to or reduced their stakes in the stock. ProShare Advisors LLC acquired a new position in USANA Health Sciences during the fourth quarter worth about $303,000. Covestor Ltd acquired a new position in USANA Health Sciences during the fourth quarter worth about $49,000. Crew Capital Management Ltd. acquired a new position in USANA Health Sciences during the fourth quarter worth about $202,000. UBS Asset Management Americas Inc. grew its holdings in USANA Health Sciences by 29.4% during the third quarter. UBS Asset Management Americas Inc. now owns 13,284 shares of the company’s stock worth $1,225,000 after acquiring an additional 3,017 shares during the period. Finally, Citigroup Inc. grew its holdings in USANA Health Sciences by 25.8% during the fourth quarter. Citigroup Inc. now owns 11,598 shares of the company’s stock worth $1,174,000 after acquiring an additional 2,378 shares during the period. 55.72% of the stock is currently owned by hedge funds and other institutional investors.
USANA Health Sciences Company Profile (Get Rating)
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include meal replacement shakes, snack bars, and other related products.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Should you invest $1,000 in USANA Health Sciences right now?
Before you consider USANA Health Sciences, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and USANA Health Sciences wasn’t on the list.
While USANA Health Sciences currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Source: marketbeat.com
